We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 5

1.
Figure 2

Figure 2. Effect of in vivo blockade of anti-VEGF-C on angiogenic markers in cornea. From: Blockade of Prolymphangiogenic VEGF-C suppresses Dry Eye Disease.

Real Time PCR analysis showing transcript levels of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in corneas of different groups. Amongst group comparisons showed significant decreased expression levels of VEGF-C, VEGF-D and VEGFR-3 in the anti-VEGF-C Ab treated group compared to the untreated group.

Sunali Goyal, et al. Arch Ophthalmol. 2012 January;130(1):84-89.
2.
Figure 5

Figure 5. Effect of in vivo blockade of anti-VEGF-C on Corneal epitheliopathy in DED. From: Blockade of Prolymphangiogenic VEGF-C suppresses Dry Eye Disease.

Corneal fluorescein staining scores were significantly decreased in the group treated with anti-VEGF-C Ab at days 5, 9 and 13 vs. the untreated group. Data from a representative experiment of three performed is shown as mean ± S.E.M; each group consisting of five mice.

Sunali Goyal, et al. Arch Ophthalmol. 2012 January;130(1):84-89.
3.
Figure 4

Figure 4. Effect of in vivo blockade of anti-VEGF-C on infiltration of CD11b+ cells in DED corneas. From: Blockade of Prolymphangiogenic VEGF-C suppresses Dry Eye Disease.

(a) Representative confocal images of whole mount corneas showing CD11b+ cells (green) in normal, untreated, and anti-VEGF-C-treated eyes. (b) Anti-VEGF-C treatment significantly decreased the number of CD11b+ cells in the dry eye corneas compared to the normal and untreated groups. Data from a representative experiment of three performed is shown as mean ± S.E.M; each group consisting of 4–5 mice.

Sunali Goyal, et al. Arch Ophthalmol. 2012 January;130(1):84-89.
4.
Figure 1

Figure 1. Effect of in vivo blockade of anti-VEGF-C on corneal lymphatics in DED. From: Blockade of Prolymphangiogenic VEGF-C suppresses Dry Eye Disease.

Representative micrographs of corneal wholemounts immunostained for CD31 (green) and LYVE-1 (red) expressions showing CD31loLYVE-1hi lymphatic vessels (orange) in (a) normal, untreated and anti-VEGF-C treated corneas (100x magnification). Morphometric evaluation showing significant decrease in (b) LC (c) LA in anti-VEGF-C Ab treated group compared to normal and untreated corneas. (Lymphatics marked by arrows; C- Cornea; L- Limbus). Data from a representative experiment of three performed is shown as mean ± S.E.M; each group consisting of four to five mice.

Sunali Goyal, et al. Arch Ophthalmol. 2012 January;130(1):84-89.
5.
Figure 3

Figure 3. Effect of in vivo blockade of anti-VEGF-C on inflammatory cytokines in the conjunctiva and lymph nodes. From: Blockade of Prolymphangiogenic VEGF-C suppresses Dry Eye Disease.

Real Time PCR analysis showing transcript levels of (a) inflammatory cytokines IL1- α, IL1-β, IL-6 and IL-17 in the conjunctiva and (b) inflammatory cytokines IL-17 and IFN-γ in the lymph nodes. Anti-VEGF-C significantly decreased levels of cytokines in the ocular surface and lymphnodes compared to the untreated group, suppressing levels close to those observed in normal (non-dry) eyes and normal lymph nodes (defined as=1). Data from a representative experiment of three performed is shown as mean ± S.E.M; each group consisting of four to five mice.

Sunali Goyal, et al. Arch Ophthalmol. 2012 January;130(1):84-89.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk